Sanofi Announces Mixed News for Zaltrap

Sanofi and Regeneron have announced varied fortunes for their cancer drug Zaltrap, with the drug gaining a quick evaluation in the USA for colorectal cancer, but failing in a late-stage prostate cancer clinical trial. Sanofi announced today that the US Food and Drug Administration (FDA)  has granted priority review of the Biologics License Application for

Continue Reading

FDA Approves Regeneron & EUSA Drugs

Regeneron Pharmaceuticals and EUSA Pharma have announced that US regulators have approved their blindness drug and leukaemia therapy, respectively. The US FDA (Food and Drug Administration) has given the okay to Regeneron’s Eylea, also known as VEGF Trap-Eye, for the treatment of patients with wet age-related Macular Degeneration at a recommended dose of 2 milligrams

Continue Reading